Literature DB >> 15677517

Complement C3 is a risk factor for the development of diabetes: a population-based cohort study.

Gunnar Engström1, Bo Hedblad, Karl-Fredrik Eriksson, Lars Janzon, Folke Lindgärde.   

Abstract

Cross-sectional studies have reported strong correlations between plasma levels of complement C3, insulin, and glucose. This prospective study explored whether elevated levels of C3, C4, and other inflammation-sensitive plasma proteins (ISPs; fibrinogen, orosomucoid, alpha1-antitrypsin, haptoglobin, and ceruloplasmin) are associated with the development of diabetes. Plasma proteins were measured in 2,815 nondiabetic healthy men, age 38-50 years, who were reexamined after a mean follow-up of 6.1 years. Diabetes development (n = 123) was studied in relation to baseline levels of plasma proteins. After adjusting for age, screening year, and glucose at baseline, the odds ratio (95% CI) for developing diabetes was 1.00, 2.4 (1.1-5.3), 2.9 (1.4-6.0), and 5.6 (2.8-10.9), respectively, for men with C3 in the 1st, 2nd, 3rd, and 4th quartiles (trend: P < 0.00001). Fibrinogen, haptoglobin, C4, and the number of elevated ISPs were also related to future diabetes in this model. Only C3 was significantly associated with diabetes development after further adjustments for potential confounders, including BMI, insulin, and other inflammatory markers. We concluded that the risk of developing diabetes is related to levels of complement C3.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15677517     DOI: 10.2337/diabetes.54.2.570

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  75 in total

Review 1.  The role of complement system in adipose tissue-related inflammation.

Authors:  Sonia I Vlaicu; Alexandru Tatomir; Dallas Boodhoo; Stefan Vesa; Petru A Mircea; Horea Rus
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

2.  C3 Polymorphism Influences Circulating Levels of C3, ASP and Lipids in Schizophrenic Patients.

Authors:  Mohamed Jalloul Nsaiba; Marc Lapointe; Hajer Mabrouk; Wahiba Douki; Lotfi Gaha; Louis Pérusse; Claude Bouchard; Besma Bel Hadj Jrad; Katherine Cianflone
Journal:  Neurochem Res       Date:  2015-02-27       Impact factor: 3.996

3.  Differential inflammatory status in rats susceptible or resistant to diet-induced obesity: effects of EPA ethyl ester treatment.

Authors:  Nerea Pérez-Echarri; Patricia Pérez-Matute; Beatriz Marcos-Gómez; Maria J Baena; Amelia Marti; J Alfredo Martínez; María Jesus Moreno-Aliaga
Journal:  Eur J Nutr       Date:  2008-09-18       Impact factor: 5.614

4.  The mannose-binding lectin pathway is a significant contributor to reperfusion injury in the type 2 diabetic heart.

Authors:  Laura R La Bonte; Betsy Dokken; Grace Davis-Gorman; Gregory L Stahl; Paul F McDonagh
Journal:  Diab Vasc Dis Res       Date:  2009-07       Impact factor: 3.291

Review 5.  Role of complement and complement regulatory proteins in the complications of diabetes.

Authors:  Pamela Ghosh; Rupam Sahoo; Anand Vaidya; Michael Chorev; Jose A Halperin
Journal:  Endocr Rev       Date:  2015-04-10       Impact factor: 19.871

6.  Weight gain in relation to plasma levels of complement factor 3: results from a population-based cohort study.

Authors:  G Engström; B Hedblad; L Janzon; F Lindgärde
Journal:  Diabetologia       Date:  2005-11-11       Impact factor: 10.122

7.  Is plasma C3 and C4 levels useful in young cerebral ischemic stroke patients? Associations with prognosis at 3 months.

Authors:  Bin Zhang; Ning Yang; Cong Gao
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

8.  Disassociated relation between plasma tumor necrosis factor-alpha, interleukin-6 and increased body weight in Amerindian women: A long-term prospective study of natural body weight variation and impaired glucose tolerance.

Authors:  Folke Lindgärde; Anders Gottsäter; Bo Ahrén
Journal:  Diabetol Metab Syndr       Date:  2010-06-08       Impact factor: 3.320

9.  Subcutaneous and visceral adipose tissue FTO gene expression and adiposity, insulin action, glucose metabolism, and inflammatory adipokines in type 2 diabetes mellitus and in health.

Authors:  Katherine Samaras; Natalia K Botelho; Donald J Chisholm; Reginald V Lord
Journal:  Obes Surg       Date:  2009-09-09       Impact factor: 4.129

10.  Alkylglycerols reduce serum complement and plasma vascular endothelial growth factor in obese individuals.

Authors:  A Parri; Montserrat Fitó; C F Torres; D Muñoz-Aguayo; H Schröder; J F Cano; L Vázquez; G Reglero; María-Isabel Covas
Journal:  Inflammopharmacology       Date:  2016-05-17       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.